Home » GlaxoSmithKline to Sell Quest Shares for $256 Million

GlaxoSmithKline to Sell Quest Shares for $256 Million

March 20, 2009

GlaxoSmithKline will sell 5.7 million shares of Quest Diagnostics for about $256 million, the London-based pharmaceutical giant said.
Triangle Business Journal

19Jan
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

GlaxoSmithKline to Sell Quest Shares for $256 Million

Upcoming Events

Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements